Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.

Julien KirchgesnerRishi J DesaiMaria C SchneeweissLaurent BeaugerieSebastian SchneeweissSeoyoung C Kim

Published in: Gut (2022)

Using validated methodologies, combination therapy with vedolizumab and thiopurines was associated with lower treatment failure compared with vedolizumab monotherapy in CD but not UC across the USA and France.

Keyphrases

combination therapy
ulcerative colitis
patients with inflammatory bowel disease
open label
study protocol
replacement therapy